Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?

Impact · against what's priced in

Glaukos (GKOS) receives a modest boost from new long-term durability data for Epioxa, which reduces the risk of future sales erosion. While the stock has rallied on several factors, the reimbursement updates are already reflected in the current valuation.

GKOS+0.60

No priced-in read yet

In context

The three-year Phase 3 extension study for Epioxa showing a 1.9-diopter improvement provides new evidence of long-term durability that supports future revenue estimates.

Read from the article alone

• biotech
• healthcare
• GKOS
• clinical trials
• glaucoma
• medical devices
• ophthalmology
• pipeline

Search tags